| 000 | 03619na a2200409 4500 | ||
|---|---|---|---|
| 999 |
_c7729 _d7729 |
||
| 003 | PC7729 | ||
| 005 | 20191018062649.0 | ||
| 008 | 130622s2013 xxx||||| |||| 00| 0 eng d | ||
| 040 | _cH12O | ||
| 041 | _aeng | ||
| 100 |
_9388 _aLahuerta Palacios, Juan José _eHematología y Hemoterapia |
||
| 245 | 0 | 0 |
_aBortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. _h[artículo] |
| 260 |
_bJournal of clinical oncology: official journal of the American Society of Clinical Oncology, _c2013 |
||
| 300 | _a31(26):3279-87. | ||
| 500 | _aFormato Vancouver: Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013 Sep 10;31(26):3279-87. | ||
| 501 | _aPMID: 23897961 | ||
| 504 | _aContiene 39 referencias | ||
| 520 | _aPURPOSE: To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III studies in transplantation-eligible patients with previously untreated myeloma. | ||
| 710 |
_9297 _aServicio de Hematología y Hemoterapia |
||
| 856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc7729.pdf _ySolicitar documento |
||
| 942 |
_n0 _2ddc _cART |
||